Join
Live feed
·
PRReleasevia Quantisnow
CTI BioPharma Corp. (DE) logo

CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia

ByQuantisnow·Wall Street's wire, on your screen.
CTIC· CTI BioPharma Corp. (DE)
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CTIC (CTI BioPharma Corp. (DE)) and more on Quantisnow.